4月8日,根据CDE官网,安进生物的「AMG 570」临床试验申请获批准(受理号:JXSL2100012)。这是一款由Amgen、VielaBio和AstraZeneca/Medimmune联合开发的,靶向BLys/ICOS的双特异性融合蛋白药物。 来源:CDE官网 BLys在B细胞的增殖方面扮演重要角色,其在B细胞膜上有3个受体,分别为BAFF-R、BCMA和TACI;ICOS是T细胞共刺激...
安进双特异性抗体AMG 570在中国获批临床 中国国家药品监督管理局药品审评中心(CDE)最新公示,安进(Amgen)公司的1类新药AMG 570获得一项临床试验默示许可,拟开发治疗系统性红斑狼疮(SLE)。公开资料显示,AMG 570是一款靶向BAFF和ICOSL的双特异性抗体,全球范围内正处于2期临床研究阶段。 截图来源:CDE官网 系统性红斑狼疮...
In healthy subjects to date, single doses of AMG 570 have been safe, well tolerated, and demonstrated pharmacodynamic activity consistent with inhibition of both ICOSL and BAFF.Funding Source(s): Amgen Inc.Laurence E ChengHailing HsuMartin Kankam...
Amgen的无杠杆自由现金流于December 2023触及5年低点,是5.964十亿。 Amgen的无杠杆自由现金流于2021 (9.017十亿, -7.4%)和2023 (5.964十亿, -45.0%)减少和于2020 (9.742十亿, +15.7%)、2022 (10.842十亿, +20.2%)和2024 (17.224十亿, +188.8%)增加。
are employed by Amgen Research (Munich) GmbH. P.K., R.K., G.Z., P.A.B., and G.R. were involved in invention and development of the antibody and are shareholders of Amgen Research (Munich) GmbH. The remaining authors declare no competing financial interests....
By targeting both BAFF and ICOSL, AMG 570 has the potential to achieve a large treatment effect size in autoimmune diseases such as SLE and rheumatoid arthritis. Disclosure of Interest H. Hsu Shareholder of: Amgen, M. Zhang Shareholder of: Amgen, K. Miner Shareholder of: Amgen, G. Kevin ...
Conclusion This study will provide safety and efficacy data for AMG 570 compared with placebo, and its adaptive trial design aims to optimize development of a novel therapy for SLE patients with inadequate response to current SOC. Acknowledgments Amgen Inc. sponsored this study.doi:10.1136/lupus-...